Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.8 SEK | +1.54% | +3.12% | +28.07% |
May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Sales 2024 * | 611M 56.67M | Sales 2025 * | 750M 69.48M | Capitalization | 672M 62.26M |
---|---|---|---|---|---|
Net income 2024 * | -67M -6.21M | Net income 2025 * | -31M -2.87M | EV / Sales 2024 * | 1.51 x |
Net Debt 2024 * | 251M 23.26M | Net Debt 2025 * | 150M 13.9M | EV / Sales 2025 * | 1.1 x |
P/E ratio 2024 * |
-10
x | P/E ratio 2025 * |
-21
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 day | -0.72% | ||
1 week | +1.88% | ||
Current month | +15.74% | ||
1 month | +19.41% | ||
3 months | +34.90% | ||
6 months | +25.55% | ||
Current year | +26.52% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 19.8 | +1.54% | 14 470 |
24-05-14 | 19.5 | +2.63% | 21,092 |
24-05-13 | 19 | -1.35% | 9,412 |
24-05-10 | 19.26 | +0.31% | 22,576 |
24-05-08 | 19.2 | 0.00% | 43,523 |
Delayed Quote Nasdaq Stockholm, May 15, 2024 at 06:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.52% | 62.09M | |
+13.25% | 74.45B | |
+11.35% | 9.18B | |
+60.16% | 5.03B | |
-12.85% | 5.02B | |
+1.60% | 3.82B | |
-19.20% | 2.41B | |
+18.73% | 2.39B | |
-27.46% | 2.27B | |
+24.62% | 2.26B |
- Stock Market
- Equities
- ORX Stock